- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: KB-003 | KB003
Compound class: Antibody
Comment: Lenzilumab is a fully human IgG1κ moncolonal antibody targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), being investigated for its immunomodulatory potential.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide searches using the variable regions of the heavy and light chains of the antibody reveal exact matches with sequences submitted with patent US8075885 B2 .
|No information available.|
|Summary of Clinical Use|
|Lenzilumab has completed Phase 2 clinical trial for uncontrolled asthma, whereas a Phase 2 study in patients with inadequately controlled rheumatoid arthritis has been terminated. A Phase 1 trial in patients with previously treated chronic myelomonocytic leukemia (CMML) is ongoing .
SARS-CoV-2 and COVID-19:Lenzilumab has been entered into clinical trial to determine if blocking GM-CSF signalling can help to alleviate the immune-mediated cytokine release syndrome in patients with severe or critical COVID-19 pneumonia. The aim would be reduce the time to recovery in hospitalised patients.
|Mechanism Of Action and Pharmacodynamic Effects|
|The antibody functionally neutralizes soluble GM-CSF. The potential clinical utility of anti-GM-CSF therapy is discussed in .
In CMML, cancer cells are hypersensitive to GM-CSF, with their cell growth and survival stimulated in the presence of very low levels of this cytokine. Using lenzilumab to neutralise GM-CSF in in vitro experiments kills CMML cells.
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT04351152||Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19||Phase 3 Interventional||Humanigen, Inc.|